Preliminary evidence of anxiolytic effects of the CRF1 receptor antagonist R317573 in the 7.5% CO2 proof-of-concept experimental model of human anxiety

Validating the inhalation of 7.5% CO2 in healthy volunteers as a human experimental medicine: a model of generalized anxiety disorder (GAD)

(2011) Jayne E Bailey et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder

(2010) Vladimir Coric et al.   DEPRESSION AND ANXIETY

Dose-dependent effects of the CRF1 receptor antagonist R317573 on regional brain activity in healthy male subjects

(2009) Mark E. Schmidt et al.   PSYCHOPHARMACOLOGY

A 6-Week Randomized, Placebo-Controlled Trial of CP-316,311 (a Selective CRH1Antagonist) in the Treatment of Major Depression

(2008) Brendon Binneman et al.   AMERICAN JOURNAL OF PSYCHIATRY

A comparison of the effects of a subtype selective and non-selective benzodiazepine receptor agonist in two CO2 models of experimental human anxiety

(2008) JE Bailey et al.   JOURNAL OF PSYCHOPHARMACOLOGY

GABA-A receptors and the response to CO2 inhalation — A translational trans-species model of anxiety?

(2008) Jayne E. Bailey et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR